Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Inozyme Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Inozyme Pharma wird ein Gewinn- und Umsatzwachstum von 7.8% bzw. 74.2% pro Jahr prognostiziert, während der Gewinn pro Aktie um 19.2% pro Jahr wachsen soll.

Wichtige Informationen

4.1%

Wachstumsrate der Gewinne

18.2%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.6%
Wachstumsrate der Einnahmen	74.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	30 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency

Jul 19

Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?

Jul 12

We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Apr 06

Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation

Dec 22

Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth

Sep 08

We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

May 22

Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency

May 07

We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely

Feb 06

Inozyme Pharma on go with early-stage INZ-701 trial in a rare calcification disorder

Jan 04

Inozyme Pharma (INZY) Investor Presentation - Slideshow

Dec 03

Inozyme Pharma EPS misses by $1.02

Nov 12

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:INZY - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	11	-141	-181	-133	7
12/31/2025	N/A	-122	-150	-116	7
12/31/2024	N/A	-101	-110	-96	7
3/31/2024	N/A	-77	-78	-77	N/A
12/31/2023	N/A	-71	-71	-71	N/A
9/30/2023	N/A	-68	-67	-67	N/A
6/30/2023	N/A	-68	-63	-62	N/A
3/31/2023	N/A	-68	-62	-61	N/A
12/31/2022	N/A	-67	-58	-58	N/A
9/30/2022	N/A	-67	-57	-57	N/A
6/30/2022	N/A	-65	-55	-55	N/A
3/31/2022	N/A	-62	-50	-50	N/A
12/31/2021	N/A	-57	-49	-48	N/A
9/30/2021	N/A	-49	-46	-46	N/A
6/30/2021	N/A	-63	-44	-43	N/A
3/31/2021	N/A	-60	-43	-42	N/A
12/31/2020	N/A	-56	-37	-36	N/A
9/30/2020	N/A	-52	-31	-30	N/A
6/30/2020	N/A	-28	-24	-24	N/A
3/31/2020	N/A	-22	-20	-20	N/A
12/31/2019	N/A	-20	-19	-19	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: INZY wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: INZY wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: INZY wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: INZY wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: INZY wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von INZY in 3 Jahren voraussichtlich hoch sein wird

Inozyme Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 7.5% to US$19.43

Price target decreased by 9.3% to US$20.50

Price target increased by 8.5% to US$22.60

Price target decreased by 13% to US$19.17

Price target increased by 8.5% to US$21.80

Price target increased to US$23.20

Recent updates

Price target decreased by 7.5% to US$19.43

New major risk - Revenue and earnings growth

Inozyme Pharma, Inc., Annual General Meeting, Jun 18, 2024

Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?

Inozyme Pharma, Inc. Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with Abcc6 Deficiency (PXE) and ENPP1 Deficiency

CEO & Chairman exercised options and sold US$52k worth of stock

New minor risk - Share price stability

Inozyme Pharma, Inc. to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency

New major risk - Revenue and earnings growth

Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward

Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy in Genomics England's Generation Study of Rare Conditions

Inozyme Pharma, Inc. Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)

New minor risk - Share price stability

Price target decreased by 9.3% to US$20.50

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Inozyme Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $60 million.

Price target increased by 8.5% to US$22.60

Inozyme Pharma, Inc. Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency

Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in Phase 1b Trial of INZ-701

Insufficient new directors

Price target decreased by 13% to US$19.17

Inozyme Pharma, Inc. Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701

Price target increased by 8.5% to US$21.80

Inozyme Pharma, Inc. Provides Business Updates

Inozyme Pharma, Inc. Announces First Self-Administration of Inz-701 in Ongoing Enpp1 Deficiency Phase 1/2 Clinical Trial

Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database

Price target increased to US$23.20

Inozyme Pharma GAAP EPS of -$0.38

Inozyme Pharma, Inc. Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)

Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency

Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?

Inozyme Pharma, Inc.(NasdaqGS:INZY) dropped from Russell 2500 Index

Inozyme Pharma, Inc. Appoints Kurt Gunter as Chief Medical Officer

Price target decreased to US$29.40

Inozyme Pharma, Inc. Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency

We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Inozyme Pharma, Inc. Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency

Price target decreased to US$30.00

Inozyme Pharma, Inc. Announces Management Changes

High number of new directors

Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation

Price target decreased to US$32.25

Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth

Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency

Inozyme Pharma, Inc.(NasdaqGS:INZY) dropped from Russell 2500 Growth Index

President exercised options and sold US$65k worth of stock

Inozyme Pharma, Inc. Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of Inz-701 in Abcc6 Deficiency

We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Senior Vice President of Finance Stephen Basso has left the company

Inozyme Pharma, Inc. Presents Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency

Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency

Member of Scientific Advisory Board has left the company

Member of Scientific Advisory Board has left the company

Member of Scientific Advisory Board has left the company

New 90-day low: US$19.96

We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely

Inozyme Pharma Announces Executive Changes

Senior VP & Chief Medical Officer has left the company

New 90-day high: US$27.90

Inozyme Pharma, Inc. Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency

Inozyme Pharma on go with early-stage INZ-701 trial in a rare calcification disorder

Inozyme Pharma (INZY) Investor Presentation - Slideshow

Inozyme Pharma EPS misses by $1.02

Inozyme Pharma Appoints Kevin B. Johnson as Senior Vice President, Regulatory Affairs

Inozyme Pharma, Inc. Announces Executive Changes

Inozyme Pharma, Inc. has completed an IPO in the amount of $112 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum